Panacea Index Logo

Command Palette

Search for a command to run...

The effect of a dietary supplement (N-oleyl-phosphatidyl-ethanolamine and epigallocatechin gallate) on dietary compliance and body fat loss in adults who are overweight: a double-blind, randomized control trial.

Lipids in health and disease
January 1, 1970
Gerald T Mangine et al. (7 authors)
Journal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to evaluate the efficacy of a supplement containing 105 mg of EGCG in improving compliance to a low-caloric diet and its effects on body composition, appetite, mood, and binge eating in overweight adults.

Results Summary

The supplement improved dietary compliance and mood at week 4, but these effects were not sustained by week 8. No significant differences were observed in body mass, body composition, hunger, or binge eating after eight weeks.

Population

Healthy, overweight adults (BMI > 25) including 15 men and 35 women.

Effective Dosage

105 mg of EGCG daily.

Duration

8 weeks.

Interactions

None mentioned.

Extracted Claims (12)
InterventionDirectionEndpointPopulationDosageImpactClaim #
a dietary supplement containing a blend of 170 mg of N-oleyl-phosphatidylethanolamine (NOPE) and 100 mg of epigallocatechin-3-gallate (EGCG)
increase
compliance to low caloric diets
-
-
has been shown to improve
#1
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
increase
maintaining a low caloric diet
healthy, overweight adults
-
significantly more compliant
#2
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
increase
mood
healthy, overweight adults
-
a significant difference in
#3
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
decrease
feelings of fatigue
healthy, overweight adults
-
a significant difference in
#4
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
decrease
feelings of confusion
healthy, overweight adults
-
a significant difference in
#5
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
decrease
feelings of tension
healthy, overweight adults
-
only feelings of tension were improved
#6
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
no change
body mass
healthy, overweight adults
-
No differences between groups
#7
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
no change
body composition
healthy, overweight adults
-
No differences between groups
#8
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
no change
feelings of hunger
healthy, overweight adults
-
No differences between groups
#9
8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise
no change
binge eating
healthy, overweight adults
-
No differences between groups
#10
a combination of 120 mg of NOPE and 105 mg of EGCG
increase
compliance to a low caloric diet
-
-
does appear to enhance
#11
a combination of 120 mg of NOPE and 105 mg of EGCG
increase
mood
-
-
improve
#12
Abstract

BACKGROUND: A dietary supplement containing a blend of 170 mg of N-oleyl-phosphatidylethanolamine (NOPE) and 100 mg of epigallocatechin-3-gallate (EGCG) has been shown to improve compliance to low caloric diets. Considering the cost of dietary ingredients, many manufacturers attempt to determine the lowest efficacious dose. Thus, the purpose of this study was to evaluate the efficacy of 8-weeks of supplementation with a daily intake of 120 mg of NOPE and 105 mg of EGCG in conjunction with a low caloric diet and regular, moderate exercise on dietary compliance in healthy, overweight adults. An additional purpose was to examine the effect of this supplement/diet/exercise paradigm on changes in body composition, sensation of appetite, mood and severity of binge eating. METHODS: Fifty healthy, overweight (BMI > 25 m·kg²) men (15) and women (35) (SUP; n = 25; 32.7 ± 13.75 y; BMI = 33.4 ± 6.2; PLA; n = 25, 34.3 ± 12.7 years; BMI = 33.2 ± 6.8) were recruited for a double-blind, placebo controlled study. Each volunteer was randomly assigned to either the supplement (SUP; n = 25) or placebo group (PLA; n = 25). Based upon a self-reported 3-day dietary recall all volunteers were recommended a 500 kcal or 30% (maximum of 1000 kcal) reduction in caloric intake. Volunteers were also encouraged to exercise 30 minutes per day, three times per week. RESULTS: Subjects in SUP were significantly more compliant (x² = 3.86, p = 0.049) in maintaining a low caloric diet at week 4, but this was not able to be maintained through the 8-week study. In addition, a significant difference in mood, feelings of fatigue and confusion were noted between the groups at week 4, but again not maintained by week 8 where only feelings of tension were improved. No differences between groups (p > 0.05) were observed for body mass, body composition, feelings of hunger, and binge eating after eight weeks. CONCLUSION: Supplementing with a combination of 120 mg of NOPE and 105 mg of EGCG does appear to enhance compliance to a low caloric diet and improve mood for 4 -weeks, but loses its effectiveness by week 8.

Medical Subject Headings (MeSH)
Adipose TissueAdultAffectAnti-Obesity AgentsCatechinDiet, ReducingDietary SupplementsDouble-Blind MethodFemaleHumansMaleMiddle AgedOverweightPatient CompliancePhosphatidylethanolaminesTime FactorsTreatment OutcomeYoung Adult
Study Links
Quality Scores
SafetyNot Assessed
Efficacy65/10
Quality75/10
Citation Metrics
Total Citations18
Citations/Year1.4
Relative Citation Ratio0.68
NIH Percentile36.7%
Research Impact Scores
APT Score0.75
Weight Score1.66
Normalized Score0.61
Related Supplements